Patients Discontinuing Anti-Obesity Jabs Put On Weight Four Times Faster Than People Using Diet and Exercise

New research suggests that patients who stop using popular weight-loss injections like Wegovy and Mounjaro may regain shed pounds much more quickly than those who stop traditional diet and exercise regimens.

Findings released in a prominent medical journal demonstrates that while overweight individuals often shed substantial amounts of their total mass while undergoing treatment, the mass returns at an average rate of nearly a kilo each month once they quit.

"Individuals using such medications need to be cognizant of the risk of quick weight regain when the medication ends," stated researcher Dr. Susan Jebb.

Such speed of recovery implies a return to original mass in about a year and a half.

Weighing Therapies

The study, which reviewed dozens of studies involving thousands of patients, compared the results of the injectable medications with conventional dieting.

Researchers emphasize that individuals who lose weight through lifestyle changes alone generally see a more gradual creep back—perhaps 100 grams monthly—once they finish.

The Reason for the Rapid Rebound

Experts propose the way of the jabs accounts for the amplified rebound.

The injections copy a body's own chemical called GLP-1, which controls appetite.

"Long-term administration of GLP-1 levels several times higher than the body's typical production might result in the system to generate a reduced amount of its own natural hormone, and could lessen sensitivity to its actions," noted Dr. Adam Collins, a nutrition specialist.

"Stopping of this hormone supplement leads to hunger is unsuppressed, making overeating far more likely."

A Chronic Condition?

The NHS suggest the injections for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.

Many experts contend that, given the significant potential of weight regain, the treatment should be considered ongoing.

This view is echoed by drug manufacturers, who state that the results "underscore the long-term nature of obesity," akin to managing conditions like high blood pressure.

Patient Testimonies

Users who have stopped the medication explain a intense resurgence of cravings.

"It was like something that goes on and I was suddenly starving," described an individual.

This challenge is exacerbated if patients have not developed sustainable dietary or behavioural changes during therapy.

Widespread Use

Survey data show that a significant number of adults in the UK have used weight-loss jabs in the past year, with demand remaining high.

• Adoption is higher among females compared to males.
• The 40s and 50s age group shows the highest level of interest.
• A large proportion access the medications through private healthcare rather than the NHS.

In conclusion, researchers stress that while these medications are powerful tools for weight loss, they are not a standalone fix and long-term success likely depends on combined lifestyle support.